1492 Capital Management’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

1492 Capital Management’s Portfolio SEEL Stock Details SEEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-26	Closed	-$117K	–	113
2023 Q2	$117K	Hold	26	–	–	0.07%	96
2023 Q1	$67.8K	Hold	26	–	–	0.04%	100
2022 Q4	$66.6K	Hold	26	–	–	0.04%	101
2022 Q3	$103K	Hold	26	–	–	0.07%	103
2022 Q2	$68K	Hold	26	–	–	0.04%	108
2022 Q1	$84K	Sell	26 -2	-7%	-$8.6K	0.04%	104
2021 Q4	$177K	Hold	28	–	–	0.09%	96
2021 Q3	$261K	Hold	28	–	–	0.13%	91
2021 Q2	$285K	Sell	28 -1	-3%	-$16.4K	0.15%	86
2021 Q1	$546K	Sell	29 -10	-26%	-$117K	0.31%	63
2020 Q4	$237K	Hold	39	–	–	0.14%	83
2020 Q3	$141K	Hold	39	–	–	0.11%	82
2020 Q2	$152K	Hold	39	–	–	0.13%	81
2020 Q1	$74K	Buy	+39	New	+$145K	0.09%	79

Other funds holding SEEL

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

GJL

Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MWM

Modera Wealth Management Westwood, New Jersey $8.34B AUM 19.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

1492 Capital Management's SEEL Position: Q3 2023 in Review

1492 Capital Management sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q3 2023, closing a stake of 26 shares — an estimated $117K sold.

1492 Capital Management first reported a position in SEEL in Q1 2020 and held it in 14 quarters. The position peaked at $546K in Q1 2021. 67 funds tracked by Wall St. Rank hold SEEL as of Q3 2023.

1492 Capital Management reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
1492 Capital Management sold 26 Seelos Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $117K.
1492 Capital Management first reported a position in Seelos Therapeutics, Inc. Common Stock in Q1 2020 and held it in 14 quarters.
1492 Capital Management's Seelos Therapeutics, Inc. Common Stock position peaked at $546K in Q1 2021.
67 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q3 2023.

Based on 1492 Capital Management's 13F filing for Q3 2023, filed 13 Nov 2023.